Literature DB >> 9475312

Life-threatening effects of discontinuing inhaled nitric oxide in children.

E Cueto1, J López-Herce, A Sánchez, A Carrillo.   

Abstract

We treated 40 children, aged between 15 d and 17 y, diagnosed with acute respiratory distress syndrome and/or pulmonary hypertension, with inhaled nitric oxide. The most frequent underlying diagnosis associated with ARDS were bronchopneumonia (eight), cardiac surgery (five), and sepsis (three). Pulmonary hypertension was secondary to cardiomyopathy in 2 patients and occurred in the postoperative period of cardiac surgery in 17 patients--the most frequent were ventricular septal defect (5), transposition of great arteries (4), and atrioventricular septal defect (3). In 11 patients, sudden discontinuation of nitric oxide induced a decrease in oxygenation associated in some of the patients with an increase in pulmonary artery pressure. In two patients discontinuation of nitric oxide induced severe pulmonary hypertension, extreme bradycardia and hypoxaemia, which required cardiopulmonary resuscitation. When exogenous nitric oxide is abruptly interrupted, hypoxaemia and pulmonary hypertension are found in some patients, due to a decrease in the nitric oxide concentration in the pulmonary circulation. This may be caused by the exogenous nitric oxide administration that may have inhibited endogenous production. We recommend making a progressive withdrawal of inhaled nitric oxide to avoid the side effects observed in the sudden discontinuation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9475312     DOI: 10.1111/j.1651-2227.1997.tb14909.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  6 in total

Review 1.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

2.  GTP cyclohydrolase I expression is regulated by nitric oxide: role of cyclic AMP.

Authors:  Sanjiv Kumar; Xutong Sun; Shruti Sharma; Saurabh Aggarwal; Kandasamy Ravi; Jeffery R Fineman; Stephen M Black
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-15       Impact factor: 5.464

3.  Inhaled nitric oxide applications in paediatric practice.

Authors:  A Bernasconi; M Beghetti
Journal:  Images Paediatr Cardiol       Date:  2002-01

4.  Protocol of a randomised controlled trial in cardiac surgical patients with endothelial dysfunction aimed to prevent postoperative acute kidney injury by administering nitric oxide gas.

Authors:  Francesco Marrazzo; Stefano Spina; Francesco Zadek; Tenzing Lama; Changhan Xu; Grant Larson; Emanuele Rezoagli; Rajeev Malhotra; Hui Zheng; Edward A Bittner; Kenneth Shelton; Serguei Melnitchouk; Nathalie Roy; Thoralf M Sundt; William D Riley; Purris Williams; Daniel Fisher; Robert M Kacmarek; Taylor B Thompson; Joseph Bonventre; Warren Zapol; Fumito Ichinose; Lorenzo Berra
Journal:  BMJ Open       Date:  2019-07-04       Impact factor: 2.692

Review 5.  Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging.

Authors:  Mauro Salas; Jim L Potenziano; Jaron Acker
Journal:  Med Devices (Auckl)       Date:  2021-01-07

Review 6.  Nitric oxide and pulmonary arterial hypertension.

Authors:  Adrian H Chester; Magdi H Yacoub; Salvador Moncada
Journal:  Glob Cardiol Sci Pract       Date:  2017-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.